Unlike for the other cancer types included, the proportion of prostate tumours with germline and somatic BRCA2 mutations was similar and approximately half of the BRCA2 alterations identified through tumour profiling are already present in the germline. This evidence concerns the gene BRCA2 and neoplasm.